A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer
© Mihaljevic et al; licensee BioMed Central Ltd. 2009
Received: 03 June 2008
Accepted: 08 January 2009
Published: 08 January 2009
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting email@example.com.
|3 Jun 2008||Submitted||Original manuscript|
|3 Jun 2008||Author responded||Author comments - Peter Buchler|
|Resubmission - Version 2|
|3 Jun 2008||Submitted||Manuscript version 2|
|14 Nov 2008||Reviewed||Reviewer Report - Sjoerd Rodenhuis|
|19 Nov 2008||Author responded||Author comments - Peter Buchler|
|Resubmission - Version 3|
|19 Nov 2008||Submitted||Manuscript version 3|
|7 Jan 2009||Author responded||Author comments - Peter Buchler|
|Resubmission - Version 4|
|7 Jan 2009||Submitted||Manuscript version 4|
|8 Jan 2009||Editorially accepted|
|8 Jan 2009||Article published||10.1186/1471-2482-9-1|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting firstname.lastname@example.org. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.